BioSpace News Archive

Be The Match BioTherapies® announced expanded support for clients in the Northern California region.

Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD today announced that it will issue its financial results press release for the fiscal 2023 first quarter ended September 30, 2022, on Tuesday, November 8, 2022 after the close of the stock market, and host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results.

RestorixHealth, the nation’s leading wound care solutions company, is pleased to announce that Jeff Bowman has joined RestorixHealth as the Division President of Post-Acute Operations.

Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a leading provider of therapeutics for men’s health, today announces the expansion of the FDA labeling for its oral erectile dysfunction (ED) drug, STENDRA (avanafil), marketed by its subsidiary, Metuchen Pharmaceuticals.

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health, wellness and serious disease has released its results for the quarter ended September 30, 2022 (Q1 FY23).

Express Scripts, the pharmacy benefits management business of Cigna Corporation’s Evernorth, announced a new strategic collaboration with Centene to make prescription medications more accessible and affordable for customers.

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic-based therapies for the prevention and treatment of disease, today announced positive results in a preclinical model of acute kidney injury (AKI), chronic kidney disease (CKD).

Anika Therapeutics, Inc. today announced that the Company plans to issue its third quarter 2022 financial results after the close of the market on Tuesday, November 8, 2022 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.

The National Cancer Center is pleased to announce the appointment of David Knorr, M.D., Ph.D., to its Scientific Advisory Board.

bioAffinity Technologies, Inc. announced the People’s Republic of China awarded a Certificate of Patent to the Company’s wholly owned subsidiary OncoSelect® for its patent “Porphyrin Compounds and Compositions Useful for Treating Cancer” that is directed to novel compounds in which porphyrins are conjugated to chemotherapeutics for selective delivery of cancer treatment.